Result of AGM

RNS Number : 3498U

Syncona Limited

28 July 2020

 

Syncona Limited

Result of Annual General Meeting  

28 July 2020

At the Annual General Meeting of the Company held today, all Resolutions as set out in the 'Notice of the 2020 Annual General Meeting' dated 25 June 2020 sent to shareholders of the Company (the "Notice") were duly passed.

Resolutions 1 to 14 were proposed as Ordinary Resolutions. Resolution 15 was proposed as a Special Resolution and Resolution 16 was proposed as an Extraordinary Resolution.

Details of the proxy voting results, which should be read alongside the Notice, are noted below:

No	Resolution	For	Discretion	Against	Abstain
1	Receive and consider the Annual Audited Financial Statements of the Company for the year ended 31 March 2020, together with the Reports of the Directors and Auditors thereon	445,660,527 (99.94%)	11,733 (0.01%)	242,263 (0.05%)	5,000
2	Re-appointment of Deloitte LLP (Guernsey Branch) as Auditors	445,642,529 (99.98%)	11,733 (0.01%)	59,979 (0.01%)	205,283
3	Authorise the Directors to determine the remuneration of the Auditors	445,902,291 (99.98%)	11,733 (0.01%)	500 (0.01%)	5,000
4	Re-elect Melanie Gee as a Director	434,255,293 (99.04%)	11,733 (0.01%)	4,156,616 (0.95%)	7,495,882
5	Re-elect Thomas Henderson as a Director	444,503,100 (99.68%)	11,733 (0.01%)	1,397,191 (0.31%)	7,500
6	Re-elect Rob Hutchinson as a Director	445,890,567 (99.98%)	11,733 (0.01%)	724 (0.01%)	16,500
7	Re-elect Nigel Keen as a Director	444,260,836 (99.62%)	11,733 (0.01%)	1,639,454 (0.37%)	7,500
8	Elect Kemal Malik as a Director	445,899,035 (99.98%)	11,733 (0.01%)	1,256 (0.01%)	7,500
9	Re-elect Nicholas Moss as a Director	445,899,567 (99.98%)	11,733 (0.01%)	724 (0.01%)	7,500
10	Re-elect Gian Piero Reverberi as a Director	445,900,291 (99.99%)	11,733 (0.01%)	0	7,500
11	Re-elect Ellen Strahlman as a Director	445,900,291 (99.99%)	11,733 (0.01%)	0	7,500
12	Approve the report on implementation of the Remuneration Policy for Non-Executive Directors	445,811,513 (99.97%)	11,733 (0.01%)	84,928 (0.02%)	11,350
13	Approve the Company's remuneration policy	445,809,247 (99.97%)	11,733 (0.01%)	84,694 (0.02%)	13,850

No	Resolution	For	Discretion	Against	Abstain
14	Authority to allot shares	443,984,459 (99.56%)	11,733 (0.01%)	1,906,318 (0.43%)	17,014
15	Authorise the Company to purchase its own shares	445,529,666 (99.92%)	109,277 (0.02%)	264,615 (0.06%)	15,965
16	Disapply pre-emption rights	425,619,468 (99.96%)	109,277 (0.03%)	20,964 (0.01%)	20,169,815

A vote withheld is not a vote in law and has not been counted in the votes for and against a resolution.

In accordance with the Listing Rule 9.6.2, a copy of all the resolutions passed other than resolutions concerning ordinary business have been submitted to the Financial Conduct Authority via the National Storage Mechanism and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

The full text of the resolutions can be found in the Notice, which is available on the Company's website at www.synconaltd.com/investors .

[ENDS]

Enquiries

Syncona Ltd

Siobhan Weaver / Annabel Clay

Tel: [phone]

Email: [e-mail]

FTI Consulting

Ben Atwell / Natalie Garland-Collins / Tim Stamper

Tel: [phone]

Email: [e-mail]  

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com .

About Syncona:

Syncona is a leading FTSE250 healthcare company focused on founding, building and funding a portfolio of global leaders in life science. Our vision is to build a sustainable, diverse portfolio of 15 - 20 companies focused on delivering transformational treatments to patients in truly innovative areas of healthcare, through which we are seeking to deliver strong risk-adjusted returns for shareholders.

We seek to partner with the best, brightest and most ambitious minds in science to build globally competitive businesses. We take a long-term view, underpinned by a strategic capital base, which provides us with control and flexibility over the management of our portfolio. We focus on delivering dramatic efficacy for patients in areas of high unmet need.

 

END

 

 

RAGPPUBPMUPUGUR